Search Results - "Bofill, J. Salvador"

The Long-HER study: clinical and molecular analysis of patients with HER2+ advanced breast cancer who become long-term survivors with trastuzumab-based therapy by Gámez-Pozo, Angelo, Pérez Carrión, Ramón M, Manso, Luis, Crespo, Carmen, Mendiola, Cesar, López-Vacas, Rocío, Berges-Soria, Julia, López, Isabel Álvarez, Margeli, Mireia, Calero, Juan L Bayo, Farre, Xavier González, Santaballa, Ana, Ciruelos, Eva M, Afonso, Ruth, Lao, Juan, Catalán, Gustavo, Gallego, José V Álvarez, López, José Miramón, Bofill, Francisco J Salvador, Borrego, Manuel Ruiz, Espinosa, Enrique, Vara, Juan A Fresno, Zamora, Pilar

“…Trastuzumab improves survival outcomes in patients with HER2+ metastatic breast cancer. The Long-Her study was designed to identify clinical and molecular…”
Get full text

Clinical practice evaluation of opioids induced constipation management in oncologic patients: The EIO-50 project by Salvador Bofill, J., Guillem Porta, V., Feyjoo, M., Anton Torres, A., Aranda Aguilar, E., Camps, C., Carrato Mena, A., Constenla Figueiras, M., Cruz Hernandez, J.J., Diaz Rubio, E., Garcia Foncillas, J., Gascon, P.N., Lopez Lopez, R., Soler, B., Escobar, Y.

Get full text

Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study by Oliveira, M., Falato, C., Cejalvo, J.M., Vila, M. Margelí, Tolosa, P., Salvador-Bofill, F.J., Cruz, J., Arumi, M., Luna, A.M., Guerra, J.A., Vidal, M., Martínez-Sáez, O., Paré, L., González-Farré, B., Sanfeliu, E., Ciruelos, E., Espinosa-Bravo, M., Pernas, S., Izarzugaza, Y., Esker, S., Fan, P.-D., Parul, P., Santhanagopal, A., Sellami, D., Villacampa, G., Ferrero-Cafiero, J.M., Pascual, T., Prat, A.

“…Patritumab deruxtecan (HER3-DXd) is a human epidermal growth factor receptor 3 (HER3)-directed antibody–drug conjugate composed of a fully human anti-HER3…”
Get full text

Ribociclib (RIB) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and central nervous system (CNS) metastases: Subgroup analysis from the phase IIIb CompLEEment-1 trial by Cottu, P.H., De Laurentiis, M., Marchetti, P., Coltelli, L., Califaretti, N., Debled, M., Patil, S., Evron, E., Duhoux, F.P., Menon-Singh, L., Wu, J., Zhou, K., Salvador Bofill, J.

Get full text

333PRibociclib (RIB) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and central nervous system (CNS) metastases: Subgroup analysis from the phase IIIb CompLEEment-1 trial by Cottu, P H, De Laurentiis, M, Marchetti, P, Coltelli, L, Califaretti, N, Debled, M, Patil, S, Evron, E, Duhoux, F P, Menon-Singh, L, Wu, J, Zhou, K, Salvador Bofill, J

“…Abstract Background CNS metastases are a risk in pts with breast cancer, with brain metastases diagnosed in 10-20% of pts. RIB, an oral, selective CDK4/6…”
Get full text

333P - Ribociclib (RIB) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and central nervous system (CNS) metastases: Subgroup analysis from the phase IIIb CompLEEment-1 trial by Cottu, P.H., De Laurentiis, M., Marchetti, P., Coltelli, L., Califaretti, N., Debled, M., Patil, S., Evron, E., Duhoux, F.P., Menon-Singh, L., Wu, J., Zhou, K., Salvador Bofill, J.

“…CNS metastases are a risk in pts with breast cancer, with brain metastases diagnosed in 10-20% of pts. RIB, an oral, selective CDK4/6 inhibitor, is approved…”
Get full text

1710PClinical practice evaluation of opioids induced constipation management in oncologic patients: The EIO-50 project by Salvador Bofill, J, Guillem Porta, V, Feyjoo, M, Anton Torres, A, Aranda Aguilar, E, Camps, C, Carrato Mena, A, Constenla Figueiras, M, Cruz Hernandez, J J, Diaz Rubio, E, Garcia Foncillas, J, Gascon, P N, Lopez Lopez, R, Soler, B, Escobar, Y

Get full text

Assessment of Treatment Response with Fulvestrant (F) 500 Mg in Standard Clinical Practice Through a Retrospective Study: Nct01509625 by Blancas, I., Fontanillas, M., Conde Herrero, V., Lao, J., Martinez de Dueñas, E., Sotelo Lezama, M., JaÉn-Morago, A., Bayo, J.L., Carabantes, F., Illaramendi, J.J., Gordón, M., Ruiz-Borrego, M., Cruz, J., García-Palomo, A., Mendiola, C., Perez-Ruiz, E., Cañada, J.M. Baena, Martínez, N., Esquerdo, G., Bofill, J. Salvador

Get full text

362PASSESSMENT OF TREATMENT RESPONSE WITH FULVESTRANT (F) 500 MG IN STANDARD CLINICAL PRACTICE THROUGH A RETROSPECTIVE STUDY: NCT01509625 by Blancas, I., Fontanillas, M., Conde Herrero, V., Lao, J., Martinez de Dueñas, E., Sotelo Lezama, M., JaÉn-Morago, A., Bayo, J.L., Carabantes, F., Illaramendi, J.J., Gordón, M., Ruiz-Borrego, M., Cruz, J., García-Palomo, A., Mendiola, C., Perez-Ruiz, E., Cañada, J.M. Baena, Martínez, N., Esquerdo, G., Bofill, J. Salvador

“…Abstract Aim: After CONFIRM study results, fulvestrant 500 mg (F500) became one of the standard treatments for patients with oestrogen receptor (ER+)…”
Get full text

Abstract OT3-1-06: CIBOMA/2004-01_GEICAM/2003-11: A randomised phase III trial assessing adjuvant capecitabine (Cap) maintenance therapy after standard chemotherapy for triple-negative early breast cancer (EBC) by Barrios, CE, Lluch, A, Ruiz-Borrego, M, Bines, J, Torrecillas, L, Carrasco, E, Segalla, JGM, Ruiz, A, Garcia-Saenz, JA, Torres, R, De la Haba-Rodriguez, J, Garcia-Martinez, E, Morales, S, Gomez, H, Salvador-Bofill, J, Hernando, A, Martin, M

“…Background: The ideal adjuvant treatment of triple negative EBC remains to be defined. CIBOMA/2004-01_GEICAM/2003-11 is a multinational randomized phase III…”
Get full text

Chronology of the arterial hypertension associated with inhibiting treatments of vascular endothelium growth factor receptor in patients with cancer by Fuentes Pradera, J., Salvador Bofill, J., Grilo Reina, A., Lopez Ladron, A., Bernabe Caro, R., Fernandez Parra, E., Gallego, I., Rodriguez de la Borbolla, M.

“…Abstract only…”
Get full text

CHRONOLOGY OF THE ARTERIAL HYPERTENSION ASSOCIATED WITH GROWTH FACTOR RECEPTOR INHIBITING TREATMENTS DERIVED FROM VASCULAR ENDOTHELIUM IN PATIENTS WITH CANCER: PP.38.503 by Fuentes Pradera, J, Grilo Reina, A, Lopez Ladron, A, Fernandez Parra, E, Bernanbe Caro, R, Rodriguez Borbolla, M, Gallego Jimenez, I, Salvador Bofill, J

Get full text

384TiPEffectiveness of olaparib plus trastuzumab in HER2[+], BRCA–mutated (BRCAm) or homologous recombination deficient (HRD) advanced breast cancer (ABC) patients (pts). The OPHELIA study by Alés-Martínez, J E, Morales, S, Fernández Abad, M, Sánchez-Rovira, P, Salvador Bofill, F J, Lahuerta, A, García-Sáenz, J A, Garau Llinas, I, Díaz Redondo, T, Ferrer, N, Carañana, V, López, R, Alonso Soler, S E, Bermejo, B, de la Haba, J, Zamora, P, Balmana, J, López-Miranda, E, Cortés, J, Llombart Cussac, A

“…Abstract Background In the OlympiAD trial the use of poly(adenosine diphosphate–ribose) polymerase inhibitor (PARPi) olaparib resulted in better…”
Get full text

Fluorouracil-Induced Aphasia by Bofill, Javier Salvador, Chaves, Manuel, Moreno, Jose Andres

Get full text

Comment: Fluorouracil-Induced Aphasia: Neurotoxicity versus Cerebral Ischemia by Serrano-Castro, Pedro J, Aguilar-Castillo, Maria J

Get full text

P5-14-22: Prospective Observational Study To Describe the Clinicopathological and Biological Characteristics and the Management of Metastatic Breast Cancer Patients Who Experienced Complete or Partial Remission or Disease Stabilization during at Least 3 Years by Zamora, P, Pérez-Carrión, R, Manso, L, Crespo, C, Mendiola, C, Alvarez-López, I, Margeli, M, Bayo-Calero, JL, González-Farre, X, Santaballa, A, Ciruelos, EM, Afonso, R, Lao, J, Catalán, G, Alvarez-Gallego, JV, Miramón-López, J, Salvador-Bofill, FJ, Ruiz-Borrego, M

“…Background Trastuzumab has shown an improvement in survival outcomes among patients with HER2+ metastatic breast cancer (MBC). Identification of pathological,…”
Get full text

A case of 6 different neoplasms by Ruiz Borrego, M, Salvador Bofill, J, Rizo Valero, A, Noguer Mediavilla, M

Get more information